Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

Jinglei Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Mingfang Zhao(First Hospital of China Medical University), Xin Li(Shanghai University of Traditional Chinese Medicine), Jingdong Zhang(Liaoning Cancer Hospital & Institute), Ping Yu(First Hospital of China Medical University), Bo Jin, Zhitu Zhu(First Affiliated Hospital of Liaoning Medical University), Lizhong Zhou(Sheng Jing Hospital), Xiujuan Qu(First Hospital of China Medical University)
PLoS ONE
December 26, 2013
10.1371/journal.pone.0083196
Cited by 21

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417